Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib

The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of lorlatinib-associated dyslipidemia differ from clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Blais, Normand, Adam, Jean-Philippe, Nguyen, John, Grégoire, Jean C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771/
https://www.ncbi.nlm.nih.gov/pubmed/36645013
http://dx.doi.org/10.3390/curroncol28010029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771/
https://www.ncbi.nlm.nih.gov/pubmed/36645013
http://dx.doi.org/10.3390/curroncol28010029

Ejemplares similares